Please try another search
Peloton Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company develops medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate includes PT2977, an oral HIF-2a inhibitor for patients with advanced or metastatic clear cell renal cell carcinoma (mRCC); PT2977 for von Hippel-Lindau disease associated renal cell carcinoma; and PT2567, an oral HIF-2a inhibitor in preclinical development for non-oncology indications, including pulmonary arterial hypertension. The company was formerly known as Damascus Pharmaceutics, Inc. and changed its name to Peloton Therapeutics, Inc. in June 2011. Peloton Therapeutics, Inc. was incorporated in 2010 and is headquartered in Dallas, Texas. As of July 30, 2019, Peloton Therapeutics, Inc. operates as a subsidiary of Merck & Co., Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review